Preethi Sundaram, Ph.D., has been our Chief Strategy Officer since January 1, 2022. Previously, since July 2021, Dr. Sundaram served as our Chief Product Development Officer. As of December 2024, Dr. Sundaram was appointed as a member of the board of directors of a privately held biotech company, Cilcare. Dr. Sundaram has more than 25 years’ experience managing and mentoring teams delivering lifesaving medicines to patients. Prior to her employment with Catalyst, since 2005, Dr. Sundaram was employed in various positions with Sanofi, including as Global Clinical Research Director, International Development from 2005-2010, Global Project Head, Multiple Therapeutic Area Programs from 2010 until 2017, Global Head and VP, Medical Operations, Primary Care Business Unit from 2017 until 2020, and since October2020, as Sanofi’s Global Head and VP, Medical Operations, General Medicines Business Unit. In that last position, Dr. Sundaram was accountable for leadership of critical global medical operational functions, including the oversight of portfolio financials and delivery of strategic milestones, as well as being responsible for the leadership of multiple portfolio management functions across all therapeutic areas in Sanofi’s Medicines Business Unit. Prior to joining Sanofi, in 2005 Dr. Sundaram served as a Project Lead, Immunoscience Development Center for Abbott Laboratories; between 2003 until 2005, Dr. Sundaram served as a medical writer and project lead at Covance; between 2001 until 2003, Dr. Sundaram served as a Clinical Director with Neurovision & Medical Services; between 1997 until 2001, Dr. Sundaram was a Graduate Teaching Assistant and Clinical Supervisor at West Norwich Hospital in Cambridge, UK; and between 1995 to 1997, Dr. Sundaram was on the clinical faculty at the Sankara Nethralaya Eye Hospital in Chennai, India. Dr. Sundaram serves on the board of directors of Clicare, a biotechnology company specializing in auditory sciences. Dr. Sundaram holds a Bachelor of Arts in Psychology from the University of Madras (India), a Bachelor of Science in Optometry from the Elite School of Optometry & Bits (India), a Doctor of Philosophy in Optometry from Anglia Ruskin University (United Kingdom), and an Executive Business Masters from the London Business School.
What is Preethi Sundaram's net worth?
The estimated net worth of Preethi Sundaram is at least $860.65 thousand as of June 11th, 2025. Dr. Sundaram owns 41,081 shares of Catalyst Pharmaceuticals stock worth more than $860,647 as of July 15th. This net worth evaluation does not reflect any other investments that Dr. Sundaram may own. Additionally, Dr. Sundaram receives a salary of $511,250.00 as Chief Strategy Officer at Catalyst Pharmaceuticals. Learn More about Preethi Sundaram's net worth.
How old is Preethi Sundaram?
Dr. Sundaram is currently 48 years old. There are 6 older executives and no younger executives at Catalyst Pharmaceuticals. The oldest executive at Catalyst Pharmaceuticals is Dr. Gary Ingenito M.D., Ph.D., Chief Medical & Regulatory Officer, who is 68 years old. Learn More on Preethi Sundaram's age.
What is Preethi Sundaram's salary?
As the Chief Strategy Officer of Catalyst Pharmaceuticals, Inc., Dr. Sundaram earns $511,250.00 per year. There are 3 executives that earn more than Dr. Sundaram. The highest earning executive at Catalyst Pharmaceuticals is Dr. Steven R. Miller Ph.D., Executive VP, COO & Chief Scientific Officer, who commands a salary of $884,700.00 per year. Learn More on Preethi Sundaram's salary.
How do I contact Preethi Sundaram?
Has Preethi Sundaram been buying or selling shares of Catalyst Pharmaceuticals?
Preethi Sundaram has not been actively trading shares of Catalyst Pharmaceuticals during the past quarter. Most recently, Preethi Sundaram sold 1,600 shares of the business's stock in a transaction on Wednesday, June 11th. The shares were sold at an average price of $26.42, for a transaction totalling $42,272.00. Following the completion of the sale, the insider now directly owns 41,081 shares of the company's stock, valued at $1,085,360.02. Learn More on Preethi Sundaram's trading history.
Who are Catalyst Pharmaceuticals' active insiders?
Catalyst Pharmaceuticals' insider roster includes Philip Coelho (Director), Richard Daly (President and CEO), Jeffrey Del Carmen (EVP, Chief Commercial Officer), Donald Denkhaus (Director), Brian Elsbernd (Chief Legal and Compliance Officer), Alicia Grande (Vice President, Chief Financial Officer and Treasurer), Alicia Grande (CFO), Molly Harper (Director), Gary Ingenito (Insider), Patrick McEnany (CEO), Steve Miller (COO), Steven Miller (COO & Chief Scientific Officer ), Preethi Sundaram (Chief Strategy Officer), and David Tierney (Director). Learn More on Catalyst Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Catalyst Pharmaceuticals?
In the last year, insiders at the biopharmaceutical company sold shares 12 times. They sold a total of 636,361 shares worth more than $14,090,792.06. The most recent insider tranaction occured on June, 11th when insider Preethi Sundaram sold 1,600 shares worth more than $42,272.00. Insiders at Catalyst Pharmaceuticals own 10.4% of the company.
Learn More about insider trades at Catalyst Pharmaceuticals. Information on this page was last updated on 6/11/2025.
